Navigation Links
NovaBay announces third quarter 2007 financial results

EMERYVILLE, CA, Nov. 15 /PRNewswire-FirstCall/ - NovaBay Pharmaceuticals, Inc. (AMEX & TSX: NBY), a biopharmaceutical company focused on developing non-antibiotic anti-infective products targeting the treatment or prevention of a wide range of bacterial and viral infections, today reported results for the third quarter ended September 30, 2007.

Net loss for the quarter ended September 30, 2007 was $1.6 million, or $0.24 per share, as compared to a net loss of $1.5 million, or $0.24 per share, for the third quarter of 2006. For the nine months ended September 30, 2007, NovaBay reported a net loss of $4.0 million, or $0.62 per share, as compared to a net loss of $4.2 million, or $0.76 per share, for the nine months ended September 30, 2006.

As of September 30, 2007, NovaBay had $6.9 million in cash, cash equivalents and investments. At September 30, 2007, there were outstanding 6,632,170 shares of common stock and 19,227,195 shares of preferred stock (which were convertible into 9,613,554 shares of common stock).

Recent Developments and Corporate Highlights:

On October 31, 2007, NovaBay completed its initial public offering of

5,000,000 shares of common stock at a price to the public of

$4.00 per share, and received net proceeds of approximately

$17.2 million after deducting underwriting discounts and commissions

of $1.4 million and other offering costs of approximately

$1.4 million. The underwriters have an option to purchase an

additional 750,000 shares of common stock until 30 days after the

closing of the IPO. Upon the closing of the IPO, all shares of

convertible preferred stock outstanding automatically converted into

9,613,554 shares of common stock. As of the closing of the initial

public offering, the Company had 21,254,474 shares of common stock

outstanding and $24.2 million in cash, cash equivalents and


At the end of September 2007, NovaBay received clearance from the

U.S. Food and Drug Administration (FDA) for its NeutroPhase woundcare

product. NeutroPhase is NovaBay's proprietary solution of

hypochlorous acid, a molecule that is naturally produced by the

body's immune system to protect against pathogens. NeutroPhase has

been cleared by the FDA as a prescription product for moistening

absorbent wound dressings, irrigating and cleaning minor cuts, minor

burns, superficial abrasions and minor irritations of the skin, and

moistening, debriding and irrigating acute and chronic dermal

lesions, such as stage I-IV pressure ulcers, stasis ulcers, leg

ulcers, diabetic foot ulcers, post-surgical wounds, first and second

degree burns, and abrasions and minor irritations of the skin.

NeutroPhase has been licensed to an affiliate of Kinetic Concepts,

Inc. for development and commercialization purposes within the field

of wound healing.

At the end of September 2007, NovaBay completed the treatment phase

of the Phase I safety trial for NVC-422, NovaBay's lead compound in a

class of antimicrobial compounds that it calls the Aganocide

compounds, for the decolonization of the nasal passages prior to

surgery. A total of 96 subjects were enrolled in the trial. NVC-422

is being developed for use prior to surgery to kill pathogens in the

nasal passages, including Methicillin-Resistant Staphylococcus aureus

(MRSA). The presence of MRSA in the nasal passages has been

associated with a significant increase in the risk of surgical

infection and our development program is aimed at reducing this risk.

During the third quarter of 2007, NovaBay initiated toxicology

studies for NVC-422 for the prevention of catheter associated urinary

tract infections, a significant source of hospital-associated

infections. An Investigational New Drug application for this

indication is expected to be filed with the FDA before the end of


During the third quarter of 2007, NovaBay continued its work to

develop its Aganocide compounds with its partner, an affiliate of

Alcon, Inc., for use in the treatment of infections in the eye, ear

and sinus and in contact lens solutions.

About NovaBay

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of non-antibiotic anti-infective compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus (MRSA). NovaBay has entered into a licensing and research collaboration agreement with an affiliate of Alcon, Inc. for use of the Aganocide compounds in the eye, ear and sinus and in contact lens solutions and a license agreement with an affiliate of Kinetic Concepts, Inc. for the use of NovaBay's NeutroPhase product in woundcare applications.

NovaBay(TM) , Aganocide(TM) and NeutroPhase(TM) are trademarks of NovaBay

Pharmaceuticals, Inc. All other trademarks and trade names are the

property of their respective owners.

Forward Looking Statements

This release contains forward-looking statements, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the development and potential benefits of, and the market opportunities for, NovaBay's product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in discovery, development, testing, regulatory approval, production and marketing of the company's product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company's intellectual property or trade secrets, the company's ability to obtain additional financing as necessary and unanticipated research and development and other costs. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.


(a development stage company)


(in thousands, except per share data)


Three Months Ended Nine Months Ended

September 30, September 30,

2006 2007 2006 2007

------------- ------------- --------------------------


License and


revenue $ 208 $ 1,444 $ 208 $ 4,392

------------- ------------- ------------- -------------

Total revenue 208 1,444 208 4,392


Operating Expenses:

Research and

development 1,122 2,051 2,441 5,580

General and

administrative 634 1,021 2,065 3,125

------------- ------------- ------------- -------------

Total operating

expenses 1,756 3,072 4,506 8,705

Other income, net 58 72 97 307

------------- ------------- ------------- -------------

Net loss $ (1,490) $ (1,556) $ (4,201) $ (4,006)

------------- ------------- ------------- -------------

------------- ------------- ------------- -------------

Basic and diluted

net loss per

share $ (0.24) $ (0.24) $ (0.76) $ (0.62)

Shares used to

compute basic and

diluted net loss

per share 6,234 6,564 5,524 6,494


(a development stage company)


(in thousands)

December 31, September 30,

2006 2007

------------- -------------



Current assets:

Cash, cash equivalents and investments $ 11,086 $ 6,881

Prepaid expenses and other current assets 226 364

------------- -------------

Total current assets 11,312 7,245

Property and equipment, net 554 912

------------- -------------

TOTAL ASSETS $ 11,866 $ 8,157

------------- -------------

------------- -------------



Current liabilities:

Accounts payable and accrued liabilities $ 886 $ 1,878

Deferred revenue 2,500 3,377

Other current liabilities - 170

------------- -------------

Total current liabilities 3,386 5,425

Deferred revenue - non-current 6,667 4,951

Other non-current liabilities - 373

------------- -------------

Total liabilities 10,053 10,749

------------- -------------

Stockholders' Equity (Deficit):

Convertible preferred stock 192 192

Common stock 63 66

Additional paid-in capital 14,620 14,207

Accumulated other comprehensive income 12 23

Accumulated deficit during development stage (13,074) (17,080)

------------- -------------

Total stockholders' equity (deficit) 1,813 (2,592)

------------- -------------


------------- -------------

------------- -------------

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
(Date:12/1/2015)... , ... December 01, 2015 , ... ... website detailing the important role that meat and poultry play in a ... and poultry, a nutrition quiz where visitors can check their “meat IQ,” a ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... firm, has announced its acquisition by Jordan Industries International, LLC (“JII”). , With ... of equipment rentals and maintenance services to hospitals, surgery centers, clinics, research labs ...
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , ... that its iconic bottle has won top honors in Beverage World Magazine’s Global Packaging ... also announced that it has been selected as a 2015 U.S.A. Taste Champion in ...
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... in the 1980s we have seen vast improvements in scientific research and discoveries, ... significant strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... of adjunctive imaging is the focus of numerous abstracts accepted for presentation here, ... 4, 2015. Nine abstracts highlight the use of Volpara Solutions’ quantitative breast ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 01, 2015 ... the addition of the "Spinal Muscular ... Trends, and Forecast 2015 - 2023" ... ) has announced the addition of ... Pipeline Assessment, Size, Growth, Trends, and Forecast ...
(Date:12/1/2015)... , Dec. 1, 2015  Eyeon Therapeutics ... novel dry eye treatments based on a charged ... drug delivery CDMO.  The product has been shown ... trial previously published.  Mark Mitchnick , MD, ... the protection to additional polymers in conjunction with ...
(Date:12/1/2015)... , Dec. 1, 2015  Athletic apparel ... founder have agreed to pay $1.35 million to ... advertised the company,s copper-infused compression clothing would relieve ... arthritis and other diseases. Tommie ... requires the company and its founder and chairman ...
Breaking Medicine Technology: